According to a new report Global Anticoagulant Reversal Drugs Market, published by KBV research, The Global Anticoagulant Reversal Drugs Market size is expected to reach $1.6 billion by 2027, rising at a market growth of 13.3% CAGR during the forecast period.
The andexanet alfa segment would exhibit promising CAGR over the forecast period owing to the increasing approval and launch of andexanet alfa in the major markets. The Centers for Medicare & Medicaid Services (CMS) in April 2020 established a J-code for Andexxa, thereby streamlining its reimbursement policies in the hospital outpatient settings. Therefore, supportive reimbursement policies for andexanet alfa in key markets would drive the segment growth throughout the forecast period.
The global anticoagulant reversal drugs market was dominated by Hospital pharmacy segment in 2020. As hospitals are the main centers where diagnosis and treatment of various types of bleeding disorders are performed, thus this segment is expected to grow significantly over the forecast period. Unstoppable bleeding due to blood-related disorders during emergency conditions will further drive the growth of the segment.
The North America market dominated the Global Anticoagulant Reversal Drugs Market by Region in 2020. The Asia Pacific would be the fastest-growing region of the global market during the forecast years. The increasing population and presence of a large number of the targeted populations in developing economies like China and India will support the regional market and contribute significantly to the market growth.
In addition to it, growing awareness regarding available treatment methods and the rising occurrence of bleeding disorders in these regions are the main factors boosting the demand for anticoagulant reversal drugs in this region.
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Boehringer Ingelheim International GmbH, CSL Limited, Bausch Health Companies, Inc., Octapharma AG, Pfizer, Inc., Fresenius SE & Co. KGaA, Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals), Dr. Reddy’s Laboratories Ltd., AMAG Pharmaceuticals, Inc. (Covis Pharma), and Alps Pharmaceutical Ind. Co., Ltd.
Global Anticoagulant Reversal Drugs Market Segmentation
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Product Type
- Andexanet Alfa
- Prothrombin Complex Concentrates
- Rest of North America
- Rest of Europe
- South Korea
- Rest of Asia Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Boehringer Ingelheim International GmbH
- CSL Limited
- Bausch Health Companies, Inc.
- Octapharma AG
- Pfizer, Inc.
- Fresenius SE & Co. KGaA
- Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
- Reddy’s Laboratories Ltd.
- AMAG Pharmaceuticals, Inc. (Covis Pharma)
- Alps Pharmaceutical Ind. Co., Ltd.